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Summary
 
T1/ST2 is an orphan receptor of unknown function that is expressed on the surface of murine
T helper cell type 2 (Th2), but not Th1 effector cells. In vitro
 
 
 
blockade of T1/ST2 signaling
with an immunoglobulin (Ig) fusion protein suppresses both differentiation to and activation of
Th2, but not Th1 effector populations. In a nascent Th2-dominated response, anti-T1/ST2
monoclonal antibody (mAb) inhibited eosinophil infiltration, interleukin 5 secretion, and IgE
production. To determine if these effects were mediated by a direct effect on Th2 cells, we
next used a murine adoptive transfer model of Th1- and Th2-mediated lung mucosal immune
responses. Administration of either T1/ST2 mAb or T1/ST2-Ig abrogated Th2 cytokine pro-
duction in vivo and the induction of an eosinophilic inflammatory response, but failed to mod-
ify Th1-mediated inflammation. Taken together, our data demonstrate an important role of
T1/ST2 in Th2-mediated inflammatory responses and suggest that T1/ST2 may prove to be a
novel target for the selective suppression of Th2 immune responses.
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W
 
hile the molecular basis underlying Th1 and Th2
differentiation still remains to be fully elucidated,
recent work has demonstrated that during the commitment
of naive cells to either pathway, distinct molecular events
occur that result in differential gene expression. In this re-
spect, the transcription factors c-maf (1) and GATA-3 (2,
3) have recently been shown to be induced in Th2 cells
and demonstrated to play an important role in Th2 cyto-
 
kine secretion. Moreover, GATA-3 not only appears to
directly regulate Th2 phenotype differentiation, but also
functions to inhibit commitment to the Th1 phenotype by
inhibiting IFN-
 
g
 
 secretion and the acquisition of the 
 
b
 
2
subunit of the IL-12 receptor (4). However, overexpres-
sion of GATA-3 in differentiated effector populations has
minimal effects on IL-4 or IFN-
 
g
 
 secretion (4), suggesting
that other as yet unidentified factors regulate Th2 cytokine
production from effector cells.
More recently, several transmembrane receptors have
been shown to be differentially expressed on Th subsets.
The CC chemokine receptors (CCR)
 
1
 
 CCR3 and CCR4
are expressed on Th2 cells, whereas CCR1 and CCR5 are
expressed on Th1 effector populations (5, 6), providing an
attractive mechanism by which Th subsets are preferentially
recruited to distinct inflammatory sites. In addition to
chemokine receptors, two members of the IL-1 receptor
superfamily, IL-1Rrp (7; subsequently identified as the IL-18
receptor [8]) and T1/ST2 (9), have also been shown to be
differentially expressed on Th cells. The IL-18 receptor is
expressed on activated Th1 cells and regulates IFN-
 
g
 
 secre-
tion, IL-12R 
 
b
 
2 expression, and Th1-mediated inflamma-
tion in vivo (10). T1/ST2, originally identified as a gene
induced by serum stimulation of fibroblasts (9), has more
recently been demonstrated to be overexpressed on Th2
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; CCR, CC
chemokine receptor; TLR, Toll-like receptor. 
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effector cells (11, 12) although its function still remains un-
clear.
In this report, we provide evidence to suggest that T1/
ST2 is more than a stable marker on the surface of Th2
cells, and demonstrate that T1/ST2 is a crucial cell surface
receptor that is required for Th2 effector responses. These
data suggest that T1/ST2, like other members of the IL-1
receptor superfamily including human Toll (hToll, Toll-
like receptor [TLR]-4), TLR-2, and the IL-18 receptor,
are critical regulators of both innate and adaptive immunity
(10, 13–15).
 
Materials and Methods
 
Generation of T1/ST2-Ig and T1/ST2 mAbs.
 
A DNA se-
quence containing the extracellular domain of T1/ST2 was PCR
amplified and cloned into an expression vector containing the
CD5 signal sequence and the hIgG1 constant region. COS cells
were transiently transfected with T1/ST2-Ig cDNA, and the re-
combinant proteins were purified via affinity chromatography
(protein A). The purity of T1/ST2-Ig was subsequently assessed
by Coomassie-stained SDS-PAGE and determined to be 
 
.
 
90%.
The identify of the T1/ST2-Ig was further confirmed by mass
spectrometry by comparing the trypsin peptides generated from
the extracted gel band with a theoretical trypsin digest (peptide
mass fingerprinting by matrix-associated laser desorption ioniza-
tion time-of-flight [MALDI-TOF] analysis). We also PCR am-
plified a DNA sequence containing the extracellular domain of a
novel Ig superfamily member identified in a murine brain cDNA
library unique to a Millennium Proprietary Database. This gene,
termed H1, was cloned into the identical vector as T1/ST2 con-
taining the CD5 signal sequence. H1-Ig failed to bind to either
T, B, or dendritic cells and unlike T1/ST2, was not detectable by
PCR analysis in resting or activated Th1 or Th2 cells (data not
shown); therefore, we used H1-Ig as an irrelevant control reagent
in some experiments. The rat anti-T1/ST2 mAb (clone 3E10)
was generated and characterized as described elsewhere (12).
 
Surface Expression of T1/ST2 on Th1 and Th2 Effector Cells.
 
Mice expressing the transgene for the DO11.10 
 
a
 
/
 
b
 
-TCR,
which recognizes residues 323–339 of chicken OVA in associa-
tion with I-A
 
d
 
, were provided by Dr. D. Loh (Washington Uni-
versity, St. Louis, MO [16]). Naive TCR transgenic CD4
 
1
 
 
 
T
cells were isolated as described (12) and cultured in complete
RPMI 1640 with OVA
 
323–339
 
 (10 
 
m
 
g/ml) and mitomycin
C–treated splenocytes in a 1:5 ratio. For Th1 phenotype devel-
opment, recombinant murine IL-12 (10 ng/ml) and neutralizing
anti–IL-4 mAb (11B11, 40 
 
m
 
g/ml; R&D Systems) were added,
and for Th2 development, recombinant murine IL-4 (10 ng/ml)
and neutralizing polyclonal anti–murine IL-12 (TOSH-2, 3 
 
m
 
g/
ml; Endogen) were used. After 5–7 d, cells were washed and re-
stimulated up to three times under identical polarizing condi-
tions. Cells were stained after 5–7 d with digoxigenin-labeled
3E10, and the number of T1/ST2-positive cells was detected by
antidigoxigenin Fab fragments (Boehringer Mannheim) conju-
gated to PE. Expression of T1/ST2 was analyzed on a FACSCal-
ibur™ (Becton Dickinson). To determine the cytokine profile at
each time point, cells were washed and a viable CD4 population
was isolated over a ficoll gradient and activated (2 
 
3
 
 10
 
5
 
/well) in
a 96-well plate for 24 h using plate-bound CD3 (2C11, 10 
 
m
 
g/ml;
PharMingen). IL-4 and IFN-
 
g
 
 levels were measured in the su-
pernatant by ELISA (Endogen).
 
In Vitro Differentiation of Effector Cells in an Accessory Cell–depen-
dent System.
 
CD4
 
1
 
 T cells from DO11.10 
 
a
 
/
 
b
 
-TCR mice
were activated as described above in the absence of exogenous
cytokines (termed neutral conditions) or in the presence of IL-12
or IL-4, together with T1/ST2-Ig (100 
 
m
 
g/ml) or hIg as the ap-
propriate isotype control. Cells were washed and replated in 96-
well plates (5 
 
3
 
 10
 
4
 
/well) together with 10
 
5
 
 splenocytes/well and
restimulated with OVA peptide, and cytokines were measured
48 h later. To determine the effect of T1/ST2-Ig in effector cells,
Th1 and Th2 cells were reactivated with OVA peptide in the
presence of either hIg or T1/ST2-Ig. In some experiments, H1-
Ig was used as a second control reagent for the specificity of T1/
ST2-Ig.
 
In Vivo Measurement of Th1- or Th2-mediated Immune Responses.
 
Recipient normal BALB/c mice were injected intravenously
with 2 
 
3
 
 10
 
6
 
 Th1 or Th2 effector cells. 24 h later, mice were ex-
posed to an aerosol of OVA (50 mg/ml) for 20 min on two con-
secutive days. 1 h before allergen exposure, mice were injected
intravenously with either 20 or 100 
 
m
 
g of mAb against T1/ST2
or 100 
 
m
 
g of rat IgG1. 24 h later, the trachea was cannulated, a
bronchoalveolar lavage (BAL) was performed as described (17),
and cytokine levels in the lavage fluid were measured by ELISA.
A second series of experiments was also performed using T1/
ST2-Ig (100 
 
m
 
g i.v.) or hIg as the appropriate isotype control.
Cytospin preparations were prepared (Shandon), stained with Gi-
emsa reagent, and a total of 200 cells were counted differentially.
Lungs were then removed, inflated with 10% neutral buffered
formalin, and paraffin embedded. 4-
 
m
 
m sections were stained for
cyanide-resistant peroxidase and counterstained with hematoxy-
lin using standard techniques. Airway inflammation was deter-
mined by semiquantitative scoring using an arbitrary system
where a score of 
 
1
 
1 represents one small focus of cells and 
 
1
 
5
indicates widespread infiltrates. All scoring was performed by an
investigator (C. Lloyd) unaware of the treatment.
 
Measurement of Airway Hyperresponsiveness.
 
Airway respon-
siveness was measured in Th2 recipient mice 24 h after the last
aerosol challenge by recording respiratory pressure curves by
whole body plethysmography (Buxco; EMKA Technologies) in
response to inhaled methacholine (Sigma Chemical Co.) at con-
centrations of 2.5–20 mg/ml for 1 min. Airway responsiveness
was expressed in enhanced pause (
 
P
 
enh
 
), a calculated value, which
correlates with measurement of airway resistance, impedance, and
intrapleural pressure in the same mouse: 
 
P
 
enh
 
 
 
5 
 
(
 
t
 
e
 
/
 
t
 
r1
 
) 
 
3
 
 Pef/Pif
(
 
t
 
e
 
 
 
5 
 
expiration time, 
 
t
 
r
 
 
 
5 
 
relaxation time, Pef 
 
5 
 
peak expiratory
flow, Pif 
 
5 
 
peak inspiratory flow) (18).
 
Active Immunization Protocol and IgE Measurement.
 
Male
BALB/c mice (15–20 g) were immunized intraperitoneally with
7.5 
 
m
 
g of OVA and 1.5 mg AI(OH)
 
3
 
 in saline on days 0 and 7.
On days 14 and 21, the mice were challenged with aerosolized
OVA (10 mg/ml) for 1 h. Control mice were challenged with
PBS instead of OVA. 1 h before antigen sensitization and chal-
lenge, the mice were injected with 100 
 
m
 
g of mAb against T1/
ST2 or 100 
 
m
 
g of rat IgG1. 24 h after the second challenge, a
BAL was performed and IL-5 levels in the BAL fluid were mea-
sured. Serum OVA-specific IgE was determined by specific
ELISA.
 
Results and Discussion
 
T1/ST2 Is Expressed on Th2, but Not Th1 Cells.
 
The
percentage of T1/ST2-positive cells increased under Th2
polarizing conditions from 5.2% after primary restimulation 
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to 41% after tertiary restimulation (Fig. 1), and correlated
with an enhanced capacity of cells to secrete IL-4 upon re-
stimulation (data not shown). Naive cells and Th1 effector
cells fail to express T1/ST2. These results extend our pre-
vious observations that the majority of IL-4– and IL-5–
producing cells either under bulk culture conditions (12) or
ex vivo from Th2-dominated immune responses (19) are
contained within the T1/ST2-positive cell populations.
Taken together, these data suggest that T1/ST2 is a useful
surface marker for identifying IL-4– and IL-5–producing
cells in vitro
 
 
 
and
 
 
 
in vivo.
 
T1/ST2 Signaling Is Important for Differentiation to Th2 Ef-
fector Cells.
 
To determine whether T1/ST2 plays a critical
role as a signaling molecule required for Th2 function, ex-
periments were performed using a T1/ST2-Ig fusion pro-
tein. Under neutral conditions, cells acquired the capacity
to secrete high levels of IL-4 (
 
<
 
1,700 ng/ml), IL-5
(
 
<
 
1,600 ng/ml), and IFN-
 
g
 
 (
 
<
 
2,500 pg/ml) upon restim-
ulation. T1/ST2-Ig treatment inhibited IL-4 and IL-5 se-
cretion by 
 
.
 
70% and resulted in a 10-fold augmentation
in IFN-
 
g
 
 production. Under Th2 polarizing conditions,
cells produced equivalent amounts of IL-4 and IL-5 as in
neutral conditions, but produced only 
 
<
 
300 pg/ml of
IFN-
 
g
 
. In the presence of T1/ST2-Ig, Th2 cytokine pro-
duction was also reduced, and a modest but reproducible
increase in IFN-
 
g
 
 secretion (
 
<
 
1,500 pg/ml) was ob-
served. In contrast to these observations, when cells were
cultured in the presence of IL-12, inhibition of T1/ST2
failed to modify IFN-
 
g
 
 production. These results are in
some respects similar to recent data generated using either
CTLA-4–Ig fusion protein to inhibit CD28/B7 interac-
tions (20) or B7-deficient APCs (21). However, in con-
trast to CD28-mediated costimulation, which is required
for optimal secretion of both IL-4 and IFN-
 
g 
 
when cells
were cultured under neutral conditions (21), inhibition of
T1/ST2 resulted in skewing of the immune response
from a Th2 to a Th1 phenotype. Moreover, while the ab-
sence of CD28 costimulation results in an attenuation of
IFN-
 
g
 
 and IL-4 secretion when cells are cultured under
either Th1 or Th2 polarizing conditions, respectively, in-
hibition of T1/ST2 signaling selectively inhibited cyto-
kine secretion from Th2 cells without modifying IFN-
 
g
 
secretion from Th1 cells (Fig. 2 A). These data suggest
that T1/ST2 delivers an important signal instructing naive
cells to switch to Th2 cytokine production.
 
T1/ST2 Signaling Is Important for Activation of Th2, but
Not Th1 Effector Cells.
 
To determine the requirement of
T1/ST2 signaling for activation of effector cells, Thp cells
were differentiated for two rounds of polarization to Th1
or Th2 effector populations. Effector populations were
then activated with peptide and APCs in the presence of
different concentrations of T1/ST2-Ig. Under these cir-
cumstances, blockade of T1/ST2 signaling reduced cyto-
kine production from Th2, but not Th1 effector cells in a
dose-dependent manner (Fig. 2 B). The specificity of the
T1/ST2-Ig protein is further supported by experiments
with the control H1-Ig protein. These studies are in
marked contrast to recent data generated using B7-defi-
cient APCs demonstrating that cytokine production from
Th1 and Th2 effector cells, respectively, is largely indepen-
dent of CD28/B7-mediated costimulation (21). Taken to-
gether, our data suggest that signaling through T1/ST2 can
account, at least in part, for CD28/B7-independent activa-
tion of Th2 but not Th1 effector cells.
 
Contribution of T1/ST2 to Cellular and Humoral Response
Induced by Active Immunization.
 
We next determined
whether T1/ST2 contributes to a nascent Th2-dominated
immune response in vivo. Mice were immunized systemi-
Figure 1. T1/ST2 is expressed on the surface
of Th2 cells. T1/ST2 expression was deter-
mined by flow cytometry on (A) splenocytes,
(B) purified naive CD41 (CD41/CD62L1),
or (C) Th2 and (D) Th1 effector populations
after primary, secondary, or tertiary restimula-
tion under the indicated polarizing conditions. 
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cally with antigen in adjuvant before allergen provocation,
and the cellular and humoral responses were evaluated.
Anti-T1/ST2 mAb was effective in inhibiting allergen-
induced lung eosinophilic inflammation, IL-5 production,
and the induction of OVA-specific IgE (Fig. 3, a–c). Taken
together, our data demonstrate that T1/ST2 is a critical
regulatory molecule for both cellular and humoral allergic
inflammation in mice in vivo.
Figure 2. T1/ST2 signaling is critical for differentiation to and activation of Th2 effector cells. (A) Cytokine production from antigen-restimulated
CD41 T cells differentiated with OVA peptide alone (Neutral Conditions), IL-12 plus anti–IL-4 mAb (Th1 polarizing Conditions), or IL-4 and anti–IL-
12 (Th2 polarizing Conditions) for 5 d in the presence of hIg (black bars) or T1/ST2-Ig (white bars). Data are shown as the mean 6 SEM of triplicate
wells and are representative of three different experiments. Statistical significance (*P , 0.01) was determined by Student’s t test. (B) Th1 and Th2 effec-
tor populations were generated by two rounds of stimulation under the appropriate conditions. Effector populations were then activated with peptide and
mitomycin C–treated splenocytes in the presence of either hIg (100 mg/ml; u) or T1/ST2-Ig (1–100 mg/ml) as indicated. In some experiments, a sec-
ond irrelevant hIg fusion protein was included (H1-Ig; j). Data are shown as the mean 6 SEM of triplicate wells and are representative of four different
experiments.899 Coyle et al.
Central Role of T1/ST2 in a Th2-, but Not Th1-driven
Mucosal Immune Response. While the above data demon-
strate an important role for T1/ST2 in a Th2-dominated
response induced by antigen and adjuvant, it is possible that
the observed effects on airway inflammation are not medi-
ated via suppression of Th2 cells, as other cell types, includ-
ing mast cells, also express T1/ST2 (22). To address this is-
sue, we next used a model of Th1 and Th2 cell adoptive
transfer (23). Aeroallergen provocation of Th1 or Th2 ef-
fector cell recipient mice resulted in either a neutrophilic
or eosinophilic lung mucosal inflammatory response, re-
spectively (23). Inhibition of T1/ST2 in OVA-exposed
Th2 recipient mice with either anti-T1/ST2 mAb (Fig. 4)
or T1/ST2-Ig (Table I) inhibited the secretion of IL-4, IL-
5, IL-6, and IL-13 in the BAL fluid by .90%. Intriguingly,
IL-10 secretion was independent of T1/ST2, suggesting ei-
ther that the majority of IL-10–producing cells are from a
population distinct from cells that produce other Th2 cy-
tokines or that the mechanisms of IL-10 secretion are regu-
lated differently from other Th2 cytokines. Administration
of anti-T1/ST2 mAb or T1/ST2-Ig also markedly sup-
pressed eosinophilic inflammation of the airways as assessed
both histologically (Fig. 5, a and b) and by analysis of the
number of eosinophils in the BAL fluid (Fig. 5 c, and Table
I). In contrast to the effects of anti-T1/ST2 mAb in Th2-
mediated inflammation, inhibition of T1/ST2 did not
modify Th1 effector responses as revealed either by IFN-g
secretion (Fig. 4) or Th1-mediated neutrophilic lung in-
flammation (Fig. 5, d–f). Likewise, using whole body ple-
thysmography (18), both anti-T1/ST2 mAb and T1/ST2-Ig
treatment suppressed the development of airway hyperre-
sponsiveness induced by OVA challenge in Th2 recipient
Figure 3. Inhibition of cellular and humoral
responses in an active immunization model by
anti-T1/ST2 mAb. 1 h before each allergen ad-
ministration, mice were injected with 100 mg of
either rat IgG1 (white bars) or anti-T1/ST2
mAb (gray bars). Untreated allergen-exposed
mice (black bars) are shown for comparison.
Data are shown as the mean 6 SEM of n 5 4–9
animals. Statistical significance (*P , 0.05) was
determined by Student’s t test.
Figure 4. Anti-T1/ST2 mAb administration
inhibits IL-4, IL-5, IL-6, and IL-13 secretion in
the BAL fluid. Allergen exposure of Th2 recipi-
ent mice resulted in marked elevations in IL-4,
IL-5, IL-6, IL-10, and IL-13 in the BAL fluid
(black bars). Cytokine levels were below the
level of detection (,10 pg/ml) in Th2 recipient
mice that were exposed to PBS (data not
shown). Mice were treated with either 20 or
100  mg of anti-T1/ST2 mAb (white bars). OVA
challenge of Th1 recipient mice (inset) resulted
in high levels of IFN-g in the BAL fluid (black
bars) that were not inhibited by T1/ST2 mAb
(white bars). Data are shown as the mean 6
SEM of n 5 5–6 animals. Statistical significance
(*P , 0.01) was determined by Student’s t test.900 T1/ST2 and Th2 Immune Responses
Figure 5. Anti-T1/ST2 mAb inhibits Th2-mediated allergic lung inflammation and airway hyperresponsiveness. Representative lung histology for
Th2 recipient, OVA-exposed (a) control isotype-treated or (b) anti-T1/ST2 mAb–treated mice. Panel c shows eosinophil number in the BAL fluid
(cells/ml 3 104) in rat Ig–treated (black bars) or anti-T1/ST2 mAb–treated Th2 recipient mice (white bars), and data are shown as mean 6 SEM of n 5
5–6 animals. Similar data were generated using T1/ST2-Ig fusion protein (data not shown). Statistical significance (*P , 0.01) was determined by Stu-
dent’s t test. In contrast to the effects of anti-T1/ST2 mAb on Th2-mediated pathology, there was no effect of T1/ST2 mAb on Th1-mediated lung pa-
thology (e) compared with Th1 recipient mice treated with control rat Ig (d), summarized in panel f where the circles represent individual mice treated
with either rat Ig (d) or anti-T1/ST2 mAb (s). Statistical significance (*P , 0.01) was determined by Student’s t test. (g) OVA exposure in control Ig–
treated, Th2 recipient mice resulted in airway hyperresponsiveness (e) compared with recipient mice that were exposed to PBS (and treated with anti-
T1/ST2 mAb; u). Pretreatment with anti-T1/ST2 mAb inhibited OVA-induced bronchial hyperresponsiveness (s). The results are shown as the
mean 6 SEM of n 5 5–10 mice.901 Coyle et al.
mice (Fig. 5 g, and Table I) or in the active immunization
model (data not shown). However, whether the ability of
T1/ST2 to suppress airway hyperresponsiveness is second-
ary to attenuated eosinophilic inflammation or is via the
suppression of other key effector molecules such as IL-13
(24, 25) remains to be determined.
In conclusion, our data suggest that T1/ST2 is more
than a useful marker for detecting Th2 cells, but plays a
crucial role in the differentiation to and activation of Th2,
but not Th1 cells. These in vitro observations are sup-
ported by in vivo data that inhibition of T1/ST2 signaling
attenuates Th2-mediated inflammatory responses without
affecting Th1-mediated inflammation. Our data add to the
increasing appreciation of IL-1 receptor superfamily mem-
bers as central regulators of a number of key events in both
innate and adaptive immunity (10, 13–15).
Table I. Suppression of Eosinophilic Lung Inflammation, IL-5, and Airway Hyperresponsiveness by Inhibition of T1/ST2
Treatment (aerosol 1 i.v.) BAL eosinophils IL-5 PD400
cells/ml 3 104 pg/ml mg/ml
PBS 1 rat Ig ,13 104 ,10 14.1 6 2.1
OVA 1 rat Ig 36.2 6 2.1 142 6 32 5.0 6 0.6
OVA 1 anti-T1/ST2 10.2 6 1.9* 23 6 6* 10.7 6 1.2*
PBS 1 hIg ,1 3 104 ,10 17.9 6 4.2
OVA 1 hIg 43.3 6 5.7 119 6 32 5.8 6 1.7
OVA 1 T1/ST2-Ig 16.1 6 3.5* 32.3 6 11.0* 14.3 6 3.0*
The effect of anti-T1/ST2 mAb or T1/ST2-Ig on the number of eosinophils and IL-5 in the BAL after Th2 transfer in mice that were exposed to
either PBS or OVA. Control mice were treated with either hIg or rat Ig as the appropriate isotype controls. Airway hyperresponsiveness is shown as
provocative dose 400 (PD400), i.e., the dose of methacholine (mg/ml) required to induce an increase of 400% from baseline Penh values. Data are
shown as the mean 6 SEM and represent n 5 4–9 mice. Statistical significance was determined by Student’s t test, and a value of *P . 0.05 was con-
sidered significant.
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